bagsholder OP : The document is a **Form 8-K** filed with the U.S. Securities and Exchange Commission (SEC) by **ARCA Biopharma, Inc.**. Here are the key points from the document:
1. **Date of the Report:** August 16, 2024.
2. **Item 8.01 - Other Events:**
  - ARCA Biopharma entered into an Agreement and Plan of Merger with Mezzio Therapeutics, Inc., referred to as the "Merger Agreement."
  - ARCA has declared a special cash dividend of **$1.59 per share** to its stockholders, which is part of the merger consideration.
  - The dividend will be paid to stockholders of record as of a certain date, which is tied to the closing of the merger.
  - The merger is contingent on certain conditions being met, and if the merger does not close, the special dividend will not be paid.
3. **Forward-Looking Statements:**
  - The document contains forward-looking statements about the merger, including expectations, plans, and anticipated results. These are subject to various risks and uncertainties.
The document provides legal and financial details regarding the merger and the special dividend but does not specify the exact ex-dividend date. For that, you'd need to refer to the company's further announcements or updates.